Moderna Receives U.S. FDA Approval for Updated COVID-19 Vaccine Targeting KP.2 Variant of SARS-CoV-2
Moderna's updated COVID-19 vaccine targeting KP.2 variant of SARS-CoV-2 has been approved by the U.S. FDA for individuals 12 years and above, with EUA granted for those 6 months through 11 years. The vaccine aims to prevent COVID-19 and is expected to be available soon.
Highlighted Terms
Related News
Pfizer and BioNTech receive FDA approval for Omicron KP.2-adapted COVID-19 vaccine for individuals 12 years and older, with emergency use authorization for those 6 months through 11 years. The vaccine is based on mRNA technology and will be available in pharmacies, hospitals, and clinics across the U.S.
Pfizer and BioNTech announced CHMP's recommendation for marketing authorization of their Omicron KP.2-adapted COVID-19 vaccine for individuals 6 months and older, pending EC review. The vaccine shows improved response against multiple Omicron JN.1 sublineages, similar to the previously authorized JN.1-adapted vaccine. Doses will ship to EU member states upon EC authorization.
Pfizer and BioNTech's Omicron KP.2-adapted Covid-19 vaccine recommended for EU authorization, pending EC decision. The vaccine targets multiple Omicron sublineages, including KP.2, LB.1, KP.3, and KP.3.1.1, showing improved response over previous versions. US FDA approved the KP.2-adapted vaccine for ages 12+, with EUA for ages 6 months to 11 years.
BioNTech SE and Pfizer received a positive recommendation from the European Medicines Agency for their Omicron KP.2-adapted COVID-19 vaccine, set for EU authorization for ages 6 months and up. The vaccine promises enhanced efficacy against several Omicron sublineages, with immediate EU distribution upon approval.
Moderna's updated COVID-19 vaccine targeting KP.2 variant of SARS-CoV-2 has been approved by the U.S. FDA for individuals 12 years and above, with EUA granted for those 6 months through 11 years. The vaccine aims to prevent COVID-19 and is expected to be available soon.
CHMP recommends marketing authorization for Pfizer and BioNTech's Omicron KP.2-adapted COVID-19 vaccine for individuals 6 months and older, pending EC approval.